EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia

The EC has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic, Rxulti (brexpiprazole), for treating schizophrenia.

Leave a Reply

Your email address will not be published. Required fields are marked *